Clinical Trials Directory

Trials / Completed

CompletedNCT01436734

Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
5 (actual)
Sponsor
University Hospital, Gentofte, Copenhagen · Academic / Other
Sex
Male
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The aim of the study was to investigate the role of the Trasylol in glucagon prevention in degradation using radioimmunoactive method with I125. Additionally different incubation time was introduced in human plasma samples after oral glucose stimulation, also in fasted and hypoglycemia blood samples from patients' type 2 diabetes. Since, the structure and the techniques for the glucagon measurement are well described nowadays.

Conditions

Interventions

TypeNameDescription
OTHERFasting glycemiano intervention
OTHERHypoglycemiaInsulin induced hypoglycemia

Timeline

Start date
2011-07-01
Primary completion
2012-12-01
Completion
2013-05-01
First posted
2011-09-20
Last updated
2015-07-14

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT01436734. Inclusion in this directory is not an endorsement.

Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125 (NCT01436734) · Clinical Trials Directory